Drug level monitoring in metastatic melanoma treatment
Part of Brain & nervous system, Cancer, Genetic & congenital, Skin clinical trials.
This trial checks how much of two drugs, encorafenib and binimetinib, remain in your blood while treating advanced melanoma that cannot be removed by surgery. The goal is to learn if drug levels affect how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have advanced melanoma (stage III or IV) that cannot be surgically removed, and it started in your skin, a mucous membrane, or an unknown location
- You are currently or will be taking encorafenib and/or binimetinib as part of your treatment
- You have health insurance through the French social security system
- You agree to participate and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how doctors use encorafenib plus binimetinib for real-world care in people with BRAF V600–mutated melanoma that can’t be removed by surgery or has spread. It may help improve understanding of which patients benefit and what happens in everyday clinical practice.
This early-phase study looks at whether people with melanoma can get the “right” follow-up (extra) treatment based on how well their cancer responds after starting targeted drugs before surgery. The goal is to improve outcomes while better matching treatment to each person’s tumor response.
This Phase 2 trial tests two targeted medicines (binimetinib and encorafenib) for melanoma that has spread to the brain. It focuses on people whose tumor has a specific BRAF V600 mutation and who have brain metastases that are progressing or need treatment.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
This trial tests a combination of targeted drugs (encorafenib and binimetinib) followed by immunotherapy (cemiplimab and fianlimab) for people with advanced melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach can shrink tumors and help control the disease.
Hear when a new Melanoma (Skin) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.